Dr. Clauw, you’ve devoted your career to the research and clinical care of patients with fibromyalgia. How do you approach the diagnosis of this illness?
Read More
Recently, the FDA gave its first two approvals for medications to treat fibromyalgia (FM): first Lyrica (pregabalin) and then Cymbalta (duloxetine). While it is nice that FM is receiving some attention from big pharma, the badge of FDA approval should be taken with a grain of salt.
Read More
It has become increasingly clear that depressed patients quite often suffer from some degree of physical pain, which may adversely impact treatment outcome. Indeed, research suggests that as the pain severity of patients increases, the odds of achieving a successful antidepressant response decreases (Bair MJ et al., Psychosom Med 2004;66:17-22).
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
KarXT (Cobenfy) is the first antipsychotic that doesn’t block dopamine. We trace the origins of this new drug to a South Asian herb used for over 5,000 years, up to the three...